Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios Dimopoulos

Showing results (31-40 of 117) with videos related to

Pageof 12
Sort By:
Annals of Hematology|April 21, 2025
Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trialsMeletios Dimopoulos, Kazutaka Sunami, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2023
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial SubanalysisSalomon Manier, Meletios Dimopoulos, Cyrille Hulin, et al.
Anticancer Research|June 30, 2016
A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human CancerPinelopi Samara, Margarita Skopeliti, Marinos L Tsiatas, et al.
International Journal of Hematology|July 4, 2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myelomaAsher A Chanan-Khan, Sagar Lonial, Donna Weber, et al.
Blood Advances|May 10, 2023
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Urology|August 16, 2005
The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology GroupGeorgios Fotios Samelis, Haralambos Kalofonos, Adamos Adamou, et al.
Respirology Case Reports|November 17, 2021
Convalescent plasma therapy in an immunocompromised patient with multiple COVID-19 flares: a case reportFrini Karaolidou, Natasa-Eleni Loutsidi, Zois Mellios, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2019
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and SubgroupsRobert Z Orlowski, Philippe Moreau, Ruben Niesvizky, et al.
Blood|November 28, 2018
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVORMeletios Dimopoulos, David Siegel, Darrell J White, et al.
Lung Cancer (Amsterdam, Netherlands)|June 27, 2003
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology GroupDimosthenis-Vasilios Skarlos, Athanassios-Meletios Dimopoulos, Paraskevas Kosmidis, et al.
Pageof 12

Showing results (31-40 of 117) with videos related to

Sort By:
Pageof 12
Annals of Hematology|April 21, 2025
Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trialsMeletios Dimopoulos, Kazutaka Sunami, Xavier Leleu, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2023
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial SubanalysisSalomon Manier, Meletios Dimopoulos, Cyrille Hulin, et al.
Anticancer Research|June 30, 2016
A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human CancerPinelopi Samara, Margarita Skopeliti, Marinos L Tsiatas, et al.
International Journal of Hematology|July 4, 2012
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myelomaAsher A Chanan-Khan, Sagar Lonial, Donna Weber, et al.
Blood Advances|May 10, 2023
Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR studySaad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Urology|August 16, 2005
The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology GroupGeorgios Fotios Samelis, Haralambos Kalofonos, Adamos Adamou, et al.
Respirology Case Reports|November 17, 2021
Convalescent plasma therapy in an immunocompromised patient with multiple COVID-19 flares: a case reportFrini Karaolidou, Natasa-Eleni Loutsidi, Zois Mellios, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 5, 2019
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and SubgroupsRobert Z Orlowski, Philippe Moreau, Ruben Niesvizky, et al.
Blood|November 28, 2018
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVORMeletios Dimopoulos, David Siegel, Darrell J White, et al.
Lung Cancer (Amsterdam, Netherlands)|June 27, 2003
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology GroupDimosthenis-Vasilios Skarlos, Athanassios-Meletios Dimopoulos, Paraskevas Kosmidis, et al.
Pageof 12